Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Bonus Article
Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityReported by Thomas Hughes. Publication Date: 4/23/2026. 
Key Points
- Instuitive Surgical hit bottom in early 2026 and is set up to rebound robustly.
- Accelerting device placement, procedure volume, and consumable supplies underpin the growth outlook.
- Competition exists but trails significantly, leaving this company with a wide moat.
- Special Report: Elon’s “Hidden” Company
Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its high valuation and slowing growth. That combination has weighed on the stock since early 2025 and is unlikely to disappear quickly. Still, the current valuation already prices in a solid growth outlook, which may understate the company’s long-term potential. Intuitive Surgical’s advantage is its dominance in robotic surgical procedures. The company is a first mover, with an installed base of more than 12,000 systems and growing. At a roughly 45X multiple on current-year earnings, valuation is a hurdle, but not an insurmountable one given the potential for meaningful upside over the next few years.
And that assumes the long-term forecasts are accurate. Historically, Intuitive Surgical often outperforms expectations, while device deployments and procedure volumes continue to rise. The more likely scenario is that ISRG continues to outperform, driving a bullish revision cycle over time. Market Overreaction Sets Up ISRG OpportunityAnalysts played a role in ISRG’s price decline in 2026. Leading up to the fiscal Q1 2026 results, the dominant trend was downward price-target revisions. The market, however, overreacted, creating a deeper-than-warranted value entry. The revision trend still points to a consensus price target that implies more than 30% upside from the key support area, and conviction behind that forecast is high. MarketBeat tracks 25 analysts; the consensus rating is Moderate Buy, with a 68% buy-side bias reflected in institutional activity. The institutional picture is notable. Institutions own more than 80% of the float and have been accumulating during the correction. Their buying accelerated into Q1 2026 and remained strong in early Q2. The trailing 12-month bought/sold balance is nearly 2-to-1 in favor of buyers, with Q1 and Q2 activity showing accelerating demand. The takeaway: ISRG appears to have a solid floor in the $445–$450 region and is positioned for a robust rebound in Q2 and later in 2026. Price action mirrors that institutional activity: declines have tended to stop near $445, followed by rebounds. The mid-Q2 setup favors another rally, with the market showing support at that critical level and advancing after the Q1 release. Technical indicators such as the MACD and stochastic are aligned, suggesting a trend-following move that could push shares back toward record highs. Key technical hurdles include the 150-day exponential moving average near $500 and resistance at prior peaks near $560 and $600. Buybacks Add Leverage and Underpin the OutlookShare repurchases are another reason the stock can reach new highs. The company is outperforming, forward estimates are improving, and buybacks have enhanced shareholder leverage. The Q1 results show more than $1.1 billion in quarterly repurchases, which reduced the share count by about 0.15% sequentially and roughly 1.3% year over year. Management also has the capacity to continue buying shares at a robust pace. Intuitive Surgical’s balance sheet reflects buybacks and acquisitions, but those factors are offset by strong cash flow and the shareholder leverage gained. Key details include reduced cash balances offset by reduced liabilities and relatively steady equity. The company remains net cash relative to total liabilities, with cash more than 3.15x liabilities—one of the stronger balance sheets on the market. That position should allow ISRG to continue repurchasing shares while maintaining financial flexibility, including its zero-debt profile. Q1 Results Trigger Market ReboundIntuitive Surgical delivered a strong Q1, reinforcing existing trends and suggesting forward estimates may be understated. Net revenue of $2.77 billion rose 23.1% year over year, beating consensus by more than 550 basis points. Growth was driven by device placements (up 17%), procedure volumes (up 17%), and instrument sales (up 23%). The installed base expanded by 12%, supporting continued gains in coming quarters, and margins improved. Adjusted net income grew 36%, outpacing the top-line by more than 1,300 basis points, and is expected to remain strong in upcoming quarters. Management’s guidance calls for full-year da Vinci system growth of approximately 14.5%, with procedures and instrument sales rising similarly. The biggest risk beyond valuation is competition. The closest challenger is Medtronic’s (NYSE: MDT) Hugo system, which has seen success in some overseas markets but remains in early rollout stages. Near-term catalysts for ISRG include the early adoption of the da Vinci 5 platform, AI-related improvements, and international expansion—Japan’s recent approval of seven new robotic procedures is a meaningful example of potential upside. |
Post a Comment
Post a Comment